About Senores Pharmaceuticals Limited
Senores Pharmaceuticals Limited a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets across various therapeutic areas and dosage forms, with a presence in Emerging Markets.
Company's business is primarily focussed on the Regulated Markets of US and Canada with presence in the Emerging Markets across 43 countries. They also manufacture critical care injectables and APIs. They have partnerships in the Regulated Markets with prominent foreign and Indian pharmaceutical companies including Prasco LLC, Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., Alkem Laboratories Limited, Sun Pharmaceuticals Industries Limited, Dr. Reddy’s Laboratories Inc. and Cipla USA Inc.
Why To Invest in Senores Pharmaceuticals Limited
The Company proposes to utilise the Net Proceeds towards funding the following objects:
- Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility;
- Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;
- Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary;
- Funding the working capital requirements of the Company;
- Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”)and Ratnatris Pharmaceutical Private Limited (“Ratnatris”), to fund their working capital requirements.
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
| Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue From Operations (Rs. Cr) | 214.5 | 35.3 | 14.1 |
| Profit After Tax (Rs. Cr) | 32.7 | 8.4 | 0.99 |
Explore Other Products
